Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | MMP1 | P03956 | 4/20 | 0.47 |
| ▸ | MMP9 | P14780 | 4/20 | 0.47 |
| ▸ | MMP13 | P45452 | 4/20 | 0.47 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.47 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6658476 | 0.82 | MMP1 (0.65) | HRH3KCNH2MMP1MMP9MMP13 | |
| SCHEMBL6756509 | 0.81 | MMP1 (0.52) | HRH3KCNH2MMP1MMP9MMP13 | |
| SCHEMBL2897169 | 0.77 | PSMB1 (0.60) | HRH3PSMB1PSMB5PSMB2KDM4E | |
| SCHEMBL6657950 | 0.76 | MMP13 (0.80) | MMP1MMP9MMP13 | |
| SCHEMBL6659751 | 0.76 | MMP13 (0.63) | HRH3KCNH2MMP1MMP9MMP13 | |
| SCHEMBL6499387 | 0.75 | ADAM17 (0.59) | HRH3KCNH2MMP1MMP9MMP13 | |
| SCHEMBL7236556 | 0.75 | HRH3 (0.51) | HRH3KCNH2MMP1MMP9MMP13 | |
| SCHEMBL6655636 | 0.73 | HRH3 (0.47) | HRH3KCNH2MMP1MMP9MMP13 | |
| SCHEMBL7258553 | 0.73 | KDM4E (0.47) | HRH3MMP1MMP9MMP13KDM4E | |
| SCHEMBL6265536 | 0.72 | ADAM17 (0.67) | MMP1MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040033988-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH (US) | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033988-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | HRH3 1098/4885KCNH2 4863/4885MMP1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.